Introduction
Epoxy resin systems (ERS) are commercial thermosetting products that are combinations of epoxy resins, curing agents, modifiers, and reactive diluents used in applications where strong, flexible, and light-weight construction materials are required. The global epoxy resin market is projected to reach over 3 million tons in annual sales by 2017. 1 Examples of their uses are in paints, adhesives, coatings and electrical laminates. Due to their technical advantages, ERS continue to find new applications. Epoxy resin monomers are polymer precursor units which are reacted with hardeners to give the polymeric material. The most commonly used epoxy resin monomers are diglycidyl ethers based on bisphenol A (DGEBA) (also known as BADGE) and bisphenol F (DGEBF or BFDGE) ( Figure 1 ). Alternatives to DGEBA and DGEBF are receiving commercial interest, as epoxy resins with a variety of properties are desired. ERS are often modified by the addition of reactive diluents, which are used mainly to reduce the viscosity and improve polymerization. Phenylglycidyl ether (PGE, Figure 1) is an example of a commonly used reactive diluent.
The main concerns with use of ERS at present are their environmental impact, their cytotoxicity and their ability to cause contact allergy. Epoxy resin monomers are among the most common causative agents of occupational contact dermatitis. 2 Skin sensitization is known to be particularly common amongst construction workers and is caused by ERS present in cement and other building materials, 3, 4 but is also frequent in newer settings such as the production of wind turbine rotor blades 5 and epoxy pipe relining. 6 Epoxy resin monomers are also implicated in nonoccupational contact allergy. 7, 8 DGEBA is included in the European baseline series for diagnosis of contact allergy. 9 ERS components other than the resin monomers have also been shown to be potent sensitizers. 10 Allergic contact dermatitis from various epoxy resin system components 6, [11] [12] [13] [14] [15] [16] [17] [18] including DGEBA and DGEBF 5, 19 has been reported. The skin sensitization potential has been investigated experimentally in vivo in mice and guinea pigs for DGEBA, 20, 21 DGEBF, 21, 22 PGE 23, 24 and others. 25 DGEBA, DGEBF and PGE are strong sensitizers in both species according to regulatory classifications. 26 A number of ERS components have been demonstrated to be cytotoxic. PGE and resorcinol diglycidyl ether are classified by IARC as possibly carcinogenic to humans (class 2B). 27 PGE is known to bind to and damage DNA in vitro. 28 DNA damage, with sufficient dose and length of exposure, will trigger apoptosis and cytotoxicity. 29 The genotoxicity of epoxides including PGE is known 30 and PGE was suggested to be a direct-acting mutagen as long ago as 1979. 31 A previous study of a series of six epoxides noted that diepoxide functionality and aromaticity increased the induction of apoptosis and cytotoxicity. 29 It has been shown that DGEBA alkylates the isolated nucleophiles 4-(p-nitrobenzyl)-pyridine and deoxyguanosine. 32 DGEBF is cytotoxic in the hepatoma cell line HepG2 33 and in intestinal Caco-2 cells. 34 DGEBA was shown to be an antagonist of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPARγ) in 3T3-L1 and 3T3-F442A preadipocytes. 35 PPARγ inhibitors cause apoptosis and cell cycle arrest in colorectal carcinoma cells. 36 In contrast, DGEBA acted as a PPARγ agonist in an ECV403 cell line. 37 Further research demonstrated that DGEBA can also induce apoptosis independently of PPARγ in both caspase-dependent and independent manners. 38, 39 In this work we sought to investigate which structural features of DGEBF are important for its skin sensitizing potency. The in vivo murine local lymph node assay (LLNA) 40 
and the in vitro
KeratinoSens™ assay 41 were used to determine the sensitizing effects of the compounds. We also assessed the in vitro cytotoxicity of DGEBF analogues in the KeratinoSens™ cell line. The chemical reactivity was investigated using a model peptide and a model amino acid to estimate the possibility of binding to reactive residues in skin proteins.
Experimental Procedures
Caution: This study involves skin sensitizing compounds which must be handled with care.
Instrumentation and Mode of Analysis. 1 H and 13 C NMR spectroscopy was performed on a Jeol Eclipse 400 spectrometer at 400 and 100 MHz, respectively, using CDCl3 solutions (residual CHCl3 δ 7.26 and CHCl3 δ 77.0 as internal standards). Electron-ionization mass spectral analysis (70 eV) was performed on a Hewlett-Packard 5973 mass spectrometer connected to a gas chromatograph (Hewlett-Packard 6890). The GC was equipped with a cool on-column capillary inlet and an HP-5MSi fused silica capillary column (30 m × 0.25 mm, 0.25 µm, Agilent Technologies, Palo Alto, CA). Helium was used as carrier gas, and the flow rate was 1.2 mL/min. The temperature program started at 70 °C for 1 min, increased by 10 °C/min, and ended at 270 °C for 5 min. For mass spectral analysis, the mass spectrometer was used in the scan mode detecting ions with m/z values ranging from 50 to 1500.
High performance liquid chromatography/mass spectrometry (LC/MS) analyses were performed using electrospray ionization (EIS) on a Hewlett-Packard 1100 HPLC/MS. The system included a vacuum degasser, a binary pump, an autoinjector, a column thermostat, a diode array detector, and a single quadrupole mass spectrometer. The HPLC was equipped with a HyPURITY C18 column (150 × 3 mm i. d., particle size 3 µm, Thermo Hypersil-Keystone, Thermo Electron Corp., Bellafonte, PA). The mobile phase consisted of 0.005% pentafluoropropanoic acid, 0.1% acetic acid, and 5% acetonitrile in water (solvent A) and 0.005% pentafluoropropanoic acid, 6 0.1% acetic acid, and 50% water in acetonitrile (solvent B). A linear gradient from 0% to 100% B in 20 min, followed by 10 min of isocratic elution was used. The flow rate was 0.40 mL/min and the column temperature was set to 40 °C. The electrospray interface was used with the following spray chamber settings: nebulizer pressure, 40 psig; capillary voltage, 3500 V; drying gas temperature, 350 °C; and drying gas flow rate, 10 L/min. Fragmentor voltage was set to 120 V. The mass spectrometer was used in scan mode detecting molecular ions with m/z values ranging from 50 to 2000. DGEBA, DGEBF, PGE and 3 (Figure 1) were purchased from Sigma-Aldrich; DGEBF was obtained as a mixture of three isomers. Resorcinol diglycidyl ether (3) was 91% pure when purchased and was further purified by column chromatography (hexane: ethyl acetate 7:3) prior to evaluation. Acetone was purchased from Merck (Darmstadt, Germany) and olive oil from Apoteket AB (Goteborg, Sweden). The peptide AcPHCKRM was purchased from Peptide 2.0 Inc. (Chantilly, USA). Unless otherwise indicated, reagents were obtained from commercial suppliers and used without further purification. TLC was performed using silica gel coated aluminium plates. The purity of both synthesized and purchased test compounds was >98% (GC/MS) before evaluation in biochemical and biological assays. added dropwise at -20 ºC and the reaction mixture was stirred for 30 min at -20 ºC. Freshly distilled triethylamine (5.2 mL, 37.3 mmol) was added to a suspension of N,Odimethylhydroxylamine hydrochloride (3.63 g, 37.6 mmol), in anhydrous DMF (20 mL). The suspension was added to the reaction mixture at 0 ºC. After 3.5 hours at 0 ºC, the reaction mixture was quenched with water (300 mL). The aqueous phase was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with HCl (1 N) (125 mL), saturated aqueous NaHCO3 (125 mL) and brine (125 mL) and were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The yellow oil was purified by column chromatography (CH3OH: CH2Cl2, 0.5: 99.5) (Rf = 0.32), to give 8 (3.22 g, 57%) as a colorless oil. 1 H NMR δ 3. 35 ESI-MS (70 eV), m/z (%) 239 (2) (M+), 209 (1), 179 (100), 135 (4), 121 (82), 104 (7), 93 (9), 76 (6), 59 (20) .
Chemical Synthesis

2-((4-(4-(2-Methoxyethoxy)benzyl)phenoxy)methyl)oxirane (1) (Scheme 1A).
4-(2-Methoxyethoxy)benzoic acid (7):
(4-tert-Butyldimethylsilyloxyphenyl)(4-(2-methoxyethoxy)phenyl)methanone (9): A solution of (4-bromophenoxy)-tert-butyldimethylsilane (97%) (5.02 mL, 5.92 g, 20 mmol) in freshly distilled THF (20.0 mL) under nitrogen atmosphere was stirred for 5 min and then cooled to -78 °C. After stirring for a further 10 min, N-butyllithium (2.5 M in hexanes) (8.4 mL, 22 mmol, 2 equiv) was added dropwise to the solution. The temperature was kept at -78 °C for 20 min, and then kept at -40 °C for 40 min. A solution of 8 (2.39 g, 10 mmol) in freshly distilled THF (15 mL) was added dropwise to the in situ generated aryllithium under nitrogen atmosphere at -78 °C. The temperature was kept at -78 °C for 1 h, then kept at -30 °C for 40 min and then kept at room temperature for 1.5 h. Aqueous HCl (1 N) (13 mL) was added and after 30 min, the biphasic mixture was partitioned between chloroform (30 mL) and water (50 mL). The organic phase was washed with saturated, aqueous NaHCO3 (3 × 100 mL). The combined organic layers were dried with anhydrous Na2SO4 and concentrated in vacuo. The yellow oil was purified by column chromatography (hexane: ethyl acetate, 5:1) (Rf = 0.22), to give 9 (3.66 g, 95%) as a (2-Methoxyethoxy)benzene (4) (Scheme 1C). A solution of KOH (12 mmol) in dry ethanol (5 mL) was added to phenol (0.49 g, 5.3 mmol) in dry ethanol (5 mL). 2-Bromo-1-methoxyethane (0.65 mL, 6.9 mmol) was added and the reaction was refluxed for 4 h. The solvent was evaporated and the residue was dissolved in ethyl acetate (70 mL). The organic layer was washed successively with HCl (1M, 50 mL), NaOH (2 M, 50 mL) and water (50 mL) and was dried over Na2SO4. The solvent was evaporated in vacuo. The product was purified by column chromatography (hexane: ethyl acetate 9:1) to yield 4 (0.22 g, 27%). 1 H NMR δ 3.45 (3H, s), 3.73 -3.76 (2H, m), 4.11-4.13 (2H, m), 6.93-6.95 (3H, m), 7.26-7.30 (2H, m). 13 (17), 59 (100), 51 (17) .
1,5-Bis(2,3-epoxypropoxy)pentane (5) (Scheme 2).
1,5-Bis(allyloxy)pentane (12):
Sodium hydride (0.62 g, 26 mmol, 5.2 equiv) was washed with hexane (20 mL × 2), suspended in anhydrous THF (40 mL) and cooled to 0 ⁰C. Pentane-1,5-diol (0.52 g, 5.0 mmol) was dissolved in anhydrous THF (20 mL) and added to the suspension. The mixture was stirred at 0 ⁰C for 10 min. Allyl bromide (1.12 mL, 13 mmol, 2.6 equiv) was added and the mixture was stirred at room temperature for 90 min before refluxing overnight. The reaction was continued until TLC indicated disappearance of the starting material. The mixture was cooled to 0 ⁰C and saturated aqueous NH4Cl (70 mL) was added slowly to quench the reaction. The aqueous layer was extracted with ethyl acetate (70 mL × 3). The combined organic fractions were washed with brine (150 mL), dried over anhydrous Na2SO4 and reduced in vacuo. (12), 127 (13), 97 (7), 85 (100), 69 (47), 57 (26).
1,5-Bis(2,3-epoxypropoxy)pentane (5):
A solution of 12 (0.7 g, 3.8 mmol) in chloroform (20 mL) was cooled to 0 ⁰C. 3-Chloroperbenzoic acid (≤77%, 1.96 g, 11.4 mmol) was added and the mixture was stirred at 0 ⁰C for 2 h. The mixture was then stirred at room temperature with further additions of 3-chloroperbenzoic acid until the reaction was complete according to TLC.
Aqueous NaOH (40 mL) (10% w/v) was added and the aqueous phase was extracted with CH2Cl2 (40 mL). The organic phase was washed with brine (40 mL), dried over anhydrous The test concentrations used were as follows: 1 and 2: 1, 5, 10, 20 and 30% (w/v); Treatments were performed daily for three consecutive days (days 0, 1, and 2). Sham treated control animals received vehicle alone. On day 5, all mice were injected intravenously via the tail vein with [methyl-3 H]thymidine (2.0 Ci/mmol, Amersham Biosciences, UK) (20 µCi) in phosphatebuffered saline (PBS, containing 137 mM NaCl, 2.7 mM KCl and 10 mM phosphate buffer, pH 7.4) (250 µL). After 5 h the mice were sacrificed, the draining lymph nodes were excised and pooled for each group, and single cell suspensions of lymph-node cells in PBS were prepared using cell strainers (Falcon, BD labware, 70 µm pore size). Cell suspensions were washed twice with PBS, precipitated with TCA (5%) and left in the refrigerator overnight. The samples were then centrifuged, resuspended in TCA (5%) (1 mL) and transferred to a scintillation cocktail (10 mL) (EcoLume, INC Radiochemicals, USA). The [methyl-3 H]thymidine incorporation into DNA was measured by β-scintillation counting on Beckman LS 6000TA Instruments. Results are expressed as mean dpm/lymph node for each experimental group and as stimulation index (SI), i.e., test group/control group ratio. Test materials that at one or more concentrations caused an SI greater than 3 were considered to be positive in the LLNA. EC3 values (the estimated concentration required to induce an SI of 3) were calculated by linear interpolation. The sensitization potency was classified to the following: ≤0.2% w/v, extreme; >0.2 to ≤2% w/v, strong; >2% w/v moderate. 26 KeratinoSens™ Assay for Sensitization and Cellular Viability. The KeratinoSens™ assay was performed as previously described in detail. 41, 42 Briefly, cells were grown for 24 h in 96well plates. The medium was then replaced with medium containing the test chemical and a final level of 1% DMSO. Each compound was tested at 12 binary dilutions in the range from 0.98 to 2000 µM. Each test plate contained seven test chemicals, six wells with the solvent control, one well with no cells for background value and five wells with the positive control cinnamic aldehyde in five different concentrations. In each repetition, three parallel replicate plates were run with this same set-up and a fourth parallel plate was prepared for cytotoxicity determination.
Cells were incubated for 48 h with the test agents, after which luciferase activity and cytotoxicity
(with the MTT assay 43 ) were determined. This full procedure was repeated three times for each chemical.
Thiol Reactivity with N-Acetyl Cysteine Methyl Ester. Compound DGEBF or 2 (1 mmol) was stirred with N-ACME (1 mmol) at 37 °C overnight in a 2:1 solution of DMSO: ammonium acetate buffer (100 mM pH 7.4). The reaction was analyzed using LC/MS (see parameters above). 
Reactivity with the Model Peptide
Results and Discussion
Chemical Synthesis
Efficient synthetic strategies were employed to produce the biaromatic compounds 1 and 2 illustrated in Figure 1 . A six-step synthesis was used to obtain the non-symmetrical compound 1 (Scheme 1, A). 2-Bromoethyl methyl ether and 4-hydroxybenzoic acid were reacted (step i) and the isolated product 7 was subsequently reacted with N,O-dimethylhydroxylamine hydrochloride to produce the Weinreb amide 8 (step ii). The amide 8 was then coupled to 1-bromo-4-tertbutyldimethylsilyloxybenzene to yield the biaromatic product 9 (step iii). After reduction (step iv) and deprotection (step v), the final product 1 was obtained by alkylation of the free phenolic group with epichlorohydrin in 32% overall yield (step vi).
Synthesis of 2 was achieved in a one-step reaction in a moderate yield of 29% (Scheme 1, B) .
The monoalkylated compound was isolated as a by-product. Synthesis of 4 was achieved from phenol in 27% yield (Scheme 1, C). Both 1 and 2 were synthesized as tools to investigate the effects of the epoxide functionalities of DGEBF and cannot be used as epoxy resin monomer replacements for polymer synthesis. Compound 1, with one terminal epoxide group and one terminal methoxy group, can only form dimers and compound 2, with two terminal methoxy groups, cannot react with itself or other epoxide-containing polymeric precursors.
Linear compounds 5 and 6 were synthesized to investigate the influence of sterical shape on the cytotoxicity of 2. A 5-carbon chain was chosen as it most closely imitates the inter-atomic distance between the two epoxide groups of DGEBF (14.47 Å for 5 compared to 14.75 Å for DGEBF) (Table S1, Supporting Information). The compound with a 7-carbon chain, 6, was also synthesized to obtain supplemental information. These linear epoxides have greater flexibility than DGEBF and hence there are a large number of conformations possible. Compounds 5 and 6 were obtained in two steps from 1,5-pentanediol and 1,7-heptanediol, respectively (Scheme 2).
The diallylic intermediates 12 and 13 were each obtained in 76% yield by refluxing the starting material with allyl bromide and sodium hydride in an inert atmosphere (step i). The final compounds are formed by epoxidation using meta-chloroperbenzoic acid (mCPBA) (step ii). The corresponding monoepoxides were observed as by-products.
Skin Sensitization Potency Studies: LLNA and KeratinoSens™
Biaromatic compounds 1 and 2 were assessed in vivo for skin sensitization potency using the murine local lymph node assay (LLNA). 44 LLNA results are expressed as EC3 values, which is the estimated concentration of a substance required to induce a 3-fold increase in sensitization compared to a control.
The EC3 value obtained for compound 1 was 74 mM (2.3% w/v) ( Figure 2 and Table S2 , Supporting Information). The stimulation index decreases for the 20% and 30% concentrations compared to that of 10%. This effect was seen in repeated LLNA experiments with 1. Previously reported LLNA EC3 values for DGEBA, DGEBF and PGE indicate that they are equipotent at 36 mM, 36 mM and 31 mM (1.2, 1.1 and 0.46% w/v), respectively. 21, 23 According to suggested regulatory classifications, all three are sensitizers of strong potency. 26 The monoepoxide 1 has reduced sensitization potency in the LLNA compared to DGEBF and is classified as a moderate sensitizer according to its EC3 value of 2.3% w/v. Compound 2 does not contain any reactive epoxide groups and was non-sensitizing in concentrations up to 30% w/v (950 mM) ( Figure 2 ). This compound did not show any dose-response relationship at the concentrations tested. The only structural difference between compound 2 and DGEBF is lack of epoxide groups in compound 2 (Figure 1) . Thus, our results show that epoxide groups are directly responsible for the skin sensitization effects of DGEBF in the LLNA.
To obtain further information, all compounds were evaluated in the in vitro KeratinoSens™ assay. 42 In this assay, compounds are rated as skin sensitizers if they induce the luciferase gene by greater than 1.5-fold at non-cytotoxic concentrations. Previously published values predict DGEBA, DGEBF and PGE to be sensitizers, giving a 1.5-fold induction at low micromolar concentrations. 21 The KeratinoSens™ assay predicts 1 as a sensitizer (Table 1) . Partial cytotoxicity of a chemical may lead to a luciferase induction in dying cells and therefore chemicals are rated as sensitizers only when luciferase induction starts at non-cytotoxic concentrations. 42 For compound 2, >1.5-fold induction can only be noted at cytotoxic concentrations, and thus 2 is classified as a non-sensitizer by this method. The KeratinoSens™ results for both biaromatic compounds are in agreement with the LLNA data.
Linear diepoxides 5 and 6 were predicted to be sensitizers by the KeratinoSens™, with maximum induction values (Imax) of 209 and 43, respectively. These compounds were not evaluated in the LLNA due to ethical considerations, but it is not surprising that they are predicted to be sensitizers as both contain two terminal, reactive epoxide groups. A structurally related compound, 1,6-hexanediol diglycidyl ether, has a reported EC3 value of 1.9% w/v, classifying it as a strong sensitizer. 25 Two monoaromatic compounds were also assessed in the KeratinoSens TM . Of these, epoxide containing compound 3 was predicted to be a skin sensitizer (Imax = 120), while non-epoxide 4 was predicted as a non-sensitizer (Imax = 1.2). Neither 3 nor 4 were assessed in the LLNA, again due to ethical considerations. On the basis of the results above, 3 would be expected to be a strong sensitizer in the LLNA due to the presence of the epoxide groups, analogous to PGE. 21 Conversely, 4 is structurally related to 2 and would not be expected to act as a sensitizer due to the lack of epoxide groups.
Reactivity Towards the Thiol Residue in Cysteine and in a Model Peptide
Small molecules react with reactive amino acid residues of proteins in the skin to form immunogenic complexes, which are then recognized by the immune systems as 'non-self' and provoke an immune response. Reactive amino acid residues that play a role in skin sensitization include cysteines (thiol), lysines (amino) and to a lesser extent arginines, histidines, methionines and tyrosines. 45 It has been previously demonstrated that the epoxy reactive diluent PGE reacts selectively with the thiol residue of a model peptide. 23 We firstly investigated the reactivity of DGEBF and compound 2 with a cysteine derivative (N-acetyl-L-cysteine methyl ester, N-ACME). LC/MS analysis of the DGEBF/N-ACME reaction after 24 hours showed the formation of both monoadducts and diadducts, indicating that DGEBF is thiol-reactive. There was no reaction between 2 and N-ACME, indicating that 2 is non-reactive towards free thiols. Further reactions of compound 2 were not investigated, but we would predict that the methoxy group is also unreactive towards other amino acids implicated in skin sensitization. The results of the reactivity experiment with N-ACME indicate that the epoxide groups of DGEBF are necessary for thiol binding.
Having confirmed that the epoxide group was required to react with cysteine, the reactivities of DGEBF, compound 1 and PGE towards a model peptide were investigated. The three compounds were chosen to investigate the relative reactivity of a biaromatic diepoxide, a biaromatic monoepoxide and a monoaromatic monoepoxide. The hexapeptide chosen, in the conditions of the assay.
The percentage peptide depletion was calculated for the three compounds ( Figure 3 and Table   S3 , Supporting Information). DGEBF and compound 1 are structurally similar with the only difference being one terminal epoxide group in compound 1 compared to two in DGEBF. The depletion is slightly faster for DGEBF compared to compound 1. The reactivity of DGEBF is similar to that of PGE at 120 min (7.1% of free peptide remaining). To confirm the latter result, a second experiment was performed in which both DGEBF and PGE were allowed to react simultaneously with the peptide. 51.5% of DGEBF-peptide adduct was formed compared to 48.5% of PGE-peptide adduct, confirming that DGEBF and PGE react with this peptide in essentially equimolar amounts.
Interestingly, the diepoxide DGEBF was observed to only form mono-adducts and did not crosslink peptides. This result is unexpected, as the ability to cross-link proteins could be a potential reason for the enhanced response of DGEBF in the LLNA over compound 1. A potential reason for the lack of cross-linking observed is that an excess of DGEBF compared to peptide is used in this assay (10:1 ratio).
A cysteine adduct was observed for all three compounds, indicated by haptenated y5 and y4 fragments in the MS, but non-haptenated y3 and y2 fragments (Table 2 and Figure S1 , Supporting Information). No adducts with lysine or other residues were observed. This is in agreement with previous results showing that the epoxides bind to cysteine residues in peptides. 23, 46 In summary, the reactivity experiments indicate that both the biaromatic and monoaromatic epoxide-containing compounds DGEBF, compound 1 and PGE can bind to thiol residues, while compound 2 cannot. This explains the lack of sensitizing effects shown by 2 in the LLNA and KeratinoSens™.
Cytotoxicity
All compounds were screened for in vitro cytotoxicity in the KeratinoSens™ cell line using the MTT assay (Table 1) . 43 The IC50 values for the four biaromatic compounds DGEBA, DGEBF, 1 and 2 fall in the low micromolar range between 22 and 69 μM. Linear diepoxide 6 (IC50=169 μM) was over 7-fold less cytotoxic compared to both DGEBA and DGEBF. Compound 5 was the least cytotoxic of the epoxide-containing compounds (IC50=284 μM). Cytotoxicity of monoaromatic diepoxide 3 (IC50=38 μM) was in the same range as that of DGEBF, 1 and 2. The monoepoxide PGE has an IC50 value of 182 μM while compound 4 did not reduce viability by 50% or more at concentrations up to 2,000 μM.
DGEBA is known both as an alkylating agent and as a PPARγ antagonist. 32, 35 It is unknown at present if DGEBA covalently modifies the PPARγ receptor. 47 It is anticipated that DGEBF causes cell death by similar mechanisms to DGEBA due to their structural similarity. The relative loss in cytotoxic potency of the two linear epoxides 5 and 6 compared to DGEBF may indicate that terminal epoxides are not the only structural feature required for potent cytotoxicity in this cell line. DGEBF and compound 2 have equipotent cytotoxicity indicating that a structurally similar compound without reactive epoxides may have a similar cytotoxicity in monolayer cell culture. This is in contrast to the results observed for skin sensitization, where the presence of epoxide groups was essential for sensitizing effects.
The nature of the alkyl chain has a large impact on in vitro cytotoxicity when comparing monoaromatic compounds PGE and 4. PGE is known to cause cell death via reactive mechanisms, including DNA-damage, 48 activation of heat shock response and antioxidant response. 49 PGE forms DNA-adducts via its epoxide group, causing cytotoxicity and apoptosis.
Compound 4 lacks the epoxide group, and therefore cannot bind to cellular thiols or cause cell death by reactive mechanisms. Our results indicate that a reactive group is necessary for the cytotoxic effect of the monoaromatic epoxides PGE and 3 in the cell line used in our study.
Conclusion
The aim of our work was to investigate the skin sensitizing potency and in vitro cytotoxicity of analogues of the epoxy resin monomer DGEBF. These results have implications for the development of new ERS components. We have shown that the skin sensitization potency of the epoxy resin monomer DGEBF is due to its terminal epoxide groups. Based on our findings, newly reported epoxy resin monomers 50, 51 would be expected to cause skin sensitization and allergic contact dermatitis as they contain terminal epoxide groups. Our results also imply that there is a need for further research to try to decrease the reactivity of the epoxide groups to a level where the contact sensitization is reduced but the polymerization capacity is still intact. We have shown that the cytotoxicity of DGEBF in monolayer cell culture may not only be dependent on the epoxide groups. Depending on the structure of alternative epoxy resins, 50-52 reduced cytotoxicity might be obtained. It is important to keep the potential adverse health effects of epoxy resins in mind when developing a new system and to assess these effects at an early stage in the development process. a KeratinoSens™ assay performed using KeratinoSens™ reporter keratinocytes, which contain a stable insertion of a luciferase gene under control of the ARE element of the AKR1C2 gene. Imax is defined as the average maximal induction of gene activity. A luciferase induction of greater than 1.5-fold at non-cytotoxic concentrations was considered to be significant for skin sensitization. All assays were performed in triplicate on at least 3 separate occasions.
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